![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 04, 2021 9:33:19 AM
It has been brought to my attention that Pedima International of Dusseldorf have listed a Sars Cov2 antigen assay named Genviro on the BfarM website (for professional use only).
The manufacturer of this device has been indicted on fraud charges in the USA, and I have reason to believe that there are serious questions to answer over the technological validity and viability of this diagnostic system, as well as the legitimacy and probity of the individuals and organisations behind it, who may be exploiting the world wide Covid pandemic to conduct securities fraud.
I note that the PEI has not conducted an independent assessment and verifrication of this technology, and that the BfarM listing is based solely on the manufacturer supplied data.
Given the aforesaid questions over the probity of this manufacturer, it follows that serious questions must also exist over the probity of the data they have supplied,and indeed, on very the Scientific basis of the detection method that they purport to have developed.
I would like to bring this matter to your attention in the hope that any required verification, regulatory and law enforcement corrective action could be taken swiftly, and that independent confirmation is prioritised, so that any concerns over the validity of the technology can be alleviated or else appropriate corrective actions taken to delist the offending test system.
Attached is a link to the US indictment :
https://www.courtlistener.com/docket/18757030/united-states-v-berman/
The BfarM test AD at issue is AT921/21 from the following list.
https://antigentest.bfarm.de/ords/f?p=110:100:12237880204503:::::&tz=1:00
Best regards,
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM